24.10.2012 • News • Piramal • Fujifilm Biotechnologies • cooperation

Fujifilm Diosynth Biotechnologies, Piramal Announce Strategic Alliance

Fujifilm Diosynth Biotechnologies has announced it has entered into a strategic alliance with Piramal Healthcare UK, whereby the two parties will offer the seamless contract development and manufacture of antibody drug conjugates (ADCs), a growing niche in the development of biopharmaceuticals.

Fujifilm Diosynth Biotechnologies is one of the world's leading providers of contract development and manufacturing services for biopharmaceuticals, whilst Piramal is a world leader in antibody drug conjugation.

For Fujifilm Diosynth Biotechnologies, this is part of an ongoing programme to expand its offering in mammalian-based biopharmaceuticals. The company recently announced an expansion of its cGMP manufacturing facilities at both its RTP, USA and Billingham, UK sites.

Interview

Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Innovation Pitch

Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.